What is a Vaccine Adjuvant?
A vaccine adjuvant is a substance added to vaccines that enhances, modulates, and prolongs the immune response to the vaccine antigen, thereby improving vaccine efficacy and reducing the amount of antigen needed for protection. 1
Core Function and Mechanism
Adjuvants work through several key mechanisms:
- Enhance immune response by amplifying the body's reaction to the vaccine antigen 2
- Reduce antigen requirements by making vaccines more immunogenic with less viral or bacterial material 2
- Modulate immune pathways by providing inflammatory cues that enable productive immune priming 3
- Prolong immune response by creating sustained antigen exposure and memory cell generation 4
Common Types in Clinical Use
Aluminum-Based Adjuvants
The most traditional and widely used adjuvants since the 1930s. Aluminum salts (alum) work by forming particles that adsorb antigens, activate inflammatory cascades, and stimulate T-cells 5. These remain the standard in most routine vaccines.
Oil-in-Water Emulsions
MF59 is a notable example used in Fluad (an influenza vaccine), representing one of the newer adjuvants approved in the United States 2. This emulsion-based adjuvant creates antigen depot effects and localized inflammation to boost immunogenicity 6.
Novel Adjuvants
Recent additions include:
- AS01B (in Shingrix for herpes zoster)
- CpG oligonucleotides (in Heplisav-B for hepatitis B)
These represent non-aluminum adjuvant technologies that directly activate immune cells like B cells and dendritic cells 7.
Clinical Relevance
When Adjuvants Matter Most
Adjuvants are particularly important for:
- Immunocompromised patients who mount weaker responses to vaccines 2
- Elderly populations with age-related immune decline 5
- Subunit and recombinant vaccines that lack the inherent immunogenicity of live vaccines 4
Safety Considerations
Large-scale safety data demonstrates that adjuvanted vaccines have comparable safety profiles to non-adjuvanted vaccines. A pooled analysis of 64 clinical trials with over 20,000 subjects receiving MF59-adjuvanted influenza vaccines showed no significant difference in autoimmune disease incidence compared to non-adjuvanted vaccines 2.
However, when administering multiple vaccines containing novel adjuvants simultaneously, consider using a non-adjuvanted option for one vaccine if both contain novel adjuvants, though vaccination should never be delayed if only adjuvanted products are available 7.
Practical Application
In immunocompromised populations (such as SLE patients), adjuvanted vaccines may provide superior seroprotection rates compared to non-adjuvanted versions, with similar side effect profiles 2. The trade-off between enhanced immunogenicity and theoretical concerns about autoimmune stimulation has been resolved in favor of using adjuvanted vaccines when needed, based on extensive clinical trial data 2.